Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study

被引:21
|
作者
Kopp, Tine Iskov [1 ,2 ]
Blinkenberg, Morten [2 ]
Petersen, Thor [3 ]
Sorensen, Per Soelberg [2 ]
Magyari, Melinda [1 ,2 ]
机构
[1] Copenhagen Univ Hosp, Rigshosp Glostrup, Dept Neurol, Danish Multiple Sclerosis Registry, DK-2600 Glostrup, Denmark
[2] Copenhagen Univ Hosp, Rigshosp Glostrup, Danish Multiple Sclerosis Ctr, Dept Neurol, DK-2600 Glostrup, Denmark
[3] Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark
关键词
Paediatric onset multiple sclerosis (POMS); Long-term outcome; Disease modifying therapies (DMT); Observational study; Disability accumulation; DOUBLE-BLIND; INTERFERON BETA-1A; RELAPSE RATE; FOLLOW-UP; MULTICENTER; PROGRESSION; BENEFIT;
D O I
10.1016/j.msard.2020.101956
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: A consensus of early treatment with disease-modifying therapies (DMT) in multiple sclerosis (MS) has been reached based on several observational and experimental studies in adults. However, paediatric onset (PO)MS appears phenotypically different from adult onset MS, characterized by increased relapse rate and pronounced radiological activity on MRI. The objective of this study was to investigate the long-term consequences of delayed treatment start in POMS on disability in a real-world, population-based setting. Methods: Based on prospectively collected data from The Danish Multiple Sclerosis Registry, we defined a cohort of MS patients with onset before the age of 18 years, who were born in 1980 or later, and started treatment with a DMT between 1998 and 2018. The POMS cohort was stratified according to treatment start within 2 years of onset (N = 140) or later (N = 151). Annualised relapse rate in each study group was compared using a negative binomial regression; and Cox proportional hazard model was used to estimate hazard ratios (HR) of time to sustained Expanded Disability Status Scale (EDSS) score 4, 6-month confirmed EDSS worsening and 6-month confirmed EDSS improvement, respectively, according to disease duration. Results: The POMS cohort had a total median follow-up time of 7.7 years (interquartile range 4.6-11.6). There was no association between risk of relapses in patients with delayed treatment start compared to earlier treatment start. Patients starting on a DMT later than 2 years after onset had a 2.52-fold increased risk of reaching sustained EDSS 4 compared to those starting within 2 years of onset (HR=2.52, 95% confidence interval (CI) =1.01-6.34). For every year increment from onset to start of first DMT, the risk of reaching sustained EDSS 4 increased by 17% (HR=1.17, 95% CI=1.05-1.30). In line with this, the risk of reaching confirmed EDSS worsening was increased by 44% compared to those starting earlier, although not statistically significant (HR=1.44, 95% CI=0.95-2.19). Starting on a DMT later was associated with 61% decreased chance of confirmed EDSS improvement compared to those starting earlier (HR=0.39, 95% CI=0.26-0.59). For every year increment from onset to starting DMT, the risk of confirmed EDSS improvement decreased by 10% (HR=0.90, 95% CI=0.84-0.96). Conclusions: Delayed treatment start in this POMS cohort was associated with shorter time to reach sustained EDSS 4 and confirmed EDSS worsening, and decreased chance of reaching confirmed EDSS improvement, and thus support early treatment start in POMS patients.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting
    Yun Gu
    Emma Brinkley
    Joan Largent
    Rachel E. Sobel
    Sara Colli
    Diamant Thaçi
    Marieke Seyger
    Zsuzsanna Szalai
    Jean-Philippe Lacour
    Mona Ståhle
    European Journal of Dermatology, 2023, 33 : 25 - 33
  • [42] Assisted reproductive technology treatment and risk of multiple sclerosis - a Danish cohort study
    Kopp, Tine Iskov
    Pinborg, Anja
    Glazer, Clara Helene
    Magyari, Melinda
    FERTILITY AND STERILITY, 2023, 119 (02) : 291 - 299
  • [43] Assisted reproductive technology treatment and risk of multiple sclerosis - a danish cohort study
    Kopp, T.
    Pinborg, A.
    Glazer, C. H.
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 464 - +
  • [44] A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting
    Gu, Yun
    Brinkley, Emma
    Largent, Joan
    Sobel, Rachel E.
    Colli, Sara
    Thaci, Diamant
    Seyger, Marieke
    Szalai, Zsuzsanna
    Lacour, Jean-Philippe
    Stahle, Mona
    EUROPEAN JOURNAL OF DERMATOLOGY, 2023, 33 (01) : 25 - 33
  • [45] Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment
    Trojano, Maria
    Butzkueven, Helmut
    Kappos, Ludwig
    Wiendl, Heinz
    Spelman, Tim
    Pellegrini, Fabio
    Pellegrini, Fabio
    Dong, Qunming
    Kondgen, Harold
    Belachew, Shibeshih
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP2 - NP2
  • [46] Ocrelizumab treatment in multiple sclerosis - a Danish population-based cohort study
    Pontieri, L.
    Blinkenberg, M.
    Bramow, S.
    Papp, V.
    Rasmussen, P. V.
    Kant, M.
    Schafer, J.
    Mathiesen, H. K.
    Jensen, M. B.
    Sirakov, G.
    Berg, J. M.
    Kopp, T. I.
    Joensen, H.
    Sellebjerg, F.
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 676 - 677
  • [47] Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study
    Pontieri, Luigi
    Blinkenberg, Morten
    Bramow, Stephan
    Papp, Viktoria
    Rasmussen, Peter, V
    Kant, Matthias
    Schaefer, Jakob
    Mathiesen, Henrik K.
    Jensen, Michael B.
    Sirakov, Georgi
    Berg, Jonas M.
    Kopp, Tine, I
    Joensen, Hanna
    Sellebjerg, Finn
    Magyari, Melinda
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (02) : 496 - 504
  • [48] Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment
    Trojano, M.
    Butzkueven, H.
    Kappos, L.
    Wiendl, H.
    Spelman, T.
    Pellegrini, F.
    Chen, Y.
    Dong, Q.
    Koendgen, H.
    Belachew, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 562 - 563
  • [49] Long-term accumulation of disability in patients with primary progressive multiple sclerosis
    Alonso, Ricardo
    Garcea, Orlando
    Cohen, Leila
    Casas, Magdalena
    Rojas, Juan Ignacio
    Lazaro, Luciana
    Silva, Berenice Anabel
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (02) : NP31 - NP32
  • [50] Corpus callosum index and long-term disability in multiple sclerosis patients
    Yaldizli, Oezguer
    Atefy, Ramin
    Gass, Achim
    Sturm, Dietrich
    Glassl, Stephanie
    Tettenborn, Barbara
    Putzki, Norman
    JOURNAL OF NEUROLOGY, 2010, 257 (08) : 1256 - 1264